Journals / MANTAR DERGİSİ / 2018 / Cilt: 9 - Sayı: 1

Fluconazole

Flukonazol

Pages
67–75
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Although fluconazole may cause a congenital anomaly syndrome in infants born to women who have received the drug in high-doses in the first trimestre, its side effects are rare.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Fluconazole is one of the most commonly-used triazoles in clinic.
📊
Key Findings & Data:Oral and intravenous pharmacokinetics of fluconazole are similar since the drug is absorbed almost completely (≥%90) from the gastrointestinal system.
💡
Conclusion & Impact:Although fluconazole may cause a congenital anomaly syndrome in infants born to women who have received the drug in high-doses in the first trimestre, its side effects are rare.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:flukonazol · kandida · Antifungal ajanlar

Abstract

Fluconazole is one of the most commonly-used triazoles in clinic. Like other azoles, it is a compound composed of aromatic rings. Fluconazole is effective against Candida albicans, C. dubliniensis, C. guilliermondii, C. kefyr, C. parapsilosis, C. lusitaniae, and C. tropicalis. C. krusei is naturally resistant to fluconazole and many strains of C. glabrata are either resistant or less sensitive. Fluconazole exerts its antifungal effects by inhibiting the synthesis of ergosterol, which is an integral part of the fungal cell membrane. Development of resistance is rare, but when occurs, it is in the form of cross-resistance to all azoles. In order to predict the therapeutic effectiveness of fluconazole in an individual case; the ratios of the maximum drug concentration (Cmax) on fluconazole concentration – time curve, the area under the curve, and the time needed to reach the serum drug concentration above minimum inhibitory concentration (Ttau) to the minimum inhibitory concentration should be taken into account. Fluconazole may be administered via oral or intravenous route. Oral and intravenous pharmacokinetics of fluconazole are similar since the drug is absorbed almost completely (≥%90) from the gastrointestinal system. Fluconazole penetrates into all body fluids, including cerebrospinal fluid and human milk. Main indications include blastomycosis, candidemia, systemic candida infections, candidiasis prophylaxis in high-risk patients, coccidioidomycosis, and cryptococcosis. In clinical usage, it is thought that fluconazole will interact favorably with anidulafungin, caspofungin, amphotericin B, or flucytosine in either simultaneous or sequential usage. Concomitant administration with other drugs which act as hepatic CYP2C9 or CYP3A4 isoenzyme substrates or prolong the QT interval requires close monitoring. Although fluconazole may cause a congenital anomaly syndrome in infants born to women who have received the drug in high-doses in the first trimestre, its side effects are rare.

Özet

Flukonazol, klinikte sık kullanılan triazollerdendir. Diğer azoller gibi, aromatik halkalar içeren bir bileşiktir. Flukonazol Candida albicans, C. dubliniensis, C. guilliermondii, C. kefyr, C. parapsilosis, C. lusitaniae ve C. tropicalis'e etkilidir. C. krusei flukonazole doğal dirençli olup C. glabrata'nın birçok suşu da dirençli veya az duyarlıdır. Flukonazol, etkisini mantar hücre membranının önemli bir parçası olan fungal sterol ergosterolün sentezini engelleyerek gerçekleştirir. Flukonazole direnç gelişmesi nadir bir olaydır; ancak gerçekleştiğinde çoğunlukla tüm azollere çapraz direnç şeklindedir. Flukonazol ile tedavi başarısını öngörmede flukonazol konsantrasyonu - zaman eğrisinde maksimum ilaç konsantrasyonunun (Cmax), eğri altında kalan alanın ve minimum inhibitör konsantrasyon üzerindeki serum ilaç konsantrasyonuna ulaşmak için gerekli sürenin (Ttau) minimum inhibitör konsantrasyon değerine oranlarının değerlendirilmesi önerilmektedir. Flukonazol, oral yolla veya intravenöz infüzyon şeklinde verilir. Tamamına yakını (%≥90) mide-bağırsak yolundan emildiği için, flukonazolün oral ve intravenöz farmakokinetiği benzerdir. Flukonazol, beyin-omurilik sıvısı da dahil olmak üzere süte ve bütün vücut sıvılarına geçer. Başlıca endikasyonları blastomikozis, kandidemi ile yaygın kandida enfeksiyonları, yüksek riskli hastalarda kandidiyaz profilaksisi, koksidiyoidomikozis ve kriptokokozistir. Klinik kullanımda anidulafungin, kaspofungin, amfoterisin B ve flusitozinle birlikte kullanılmasının olumlu etkileşimlerle sonuçlanabileceği düşünülmektedir. Hepatik CYP2C9 veya CYP3A4 izoenzimlerin substratı olarak işlev gören ve QT aralığını uzatan diğer ilaçlarla birlikte kullanımı, yakın izlem gerektirir. Gebeliklerinin ilk trimesterinde yüksek dozda flukonazol alan kadınların bebeklerinde konjenital bir anomali sendromuna neden olabilse de yan etkileri nadirdir.

🔖

Cite This Article

ÖNCEL, S., KEÇELİ, S. A. (2018). Fluconazole. MANTAR DERGİSİ, Cilt: 9 - Sayı: 1, 67–75. https://ajindex.com/articles/279280

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. American Society of Health System Pharmacists, Inc., DynaMed [Internet]. Ipswich (MA): EBSCO Information Services. 1995 -. Record No. 233400, Fluconazole; [updated 2011 Aug 03, cited 2017 Dec 13]; [about 45 screens]. Available from http://search.ebscohost.com/login.aspx?direct=true&db=dnh&AN=233400&site=dynamed-live&scope=site.
  2. Andes D., Marchillo K., Conklin R., et al., Pharmacodynamics of a new triazole, posaconazole, in a murine model of disseminated candidiasis, Antimicrob. Agents Chemother. 48(1):137-142 (2004).
  3. Andes D., Marchillo K., Stamstad T., Conklin R., In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother, 47(10):3165-3169 (2003). Andes D., van Ogtrop M., Characterization and quantitation of the pharmacodynamics of fluconazole in a neutropenic murine disseminated candidiasis infection model, Antimicrob. Agents Chemother., 43(9):2116-2120 (1999).
  4. Arca E., Taştan H. B., Akar A., Kurumlu Z., Gür A. R., An open, randomized, comparative study of oral fluconazole, itraconazole and terbinafine therapy in onychomycosis, J. Dermatolog. Treat., 13(1):3-9 (2002).
  5. Barchiesi F., Schimizzi A. M., Caselli F., et al., Interactions between triazoles and amphotericin B against Cryptococcus neoformans. Antimicrob. Agents Chemother., 44(9):2435-2441 (2000).
  6. Bii C. C., Kose J., Taguchi H., et al., Pneumocystis jirovecii and microbiological findings in children with severe pneumonia in Nairobi, Kenya, Int. J. Tuberc. Lung Dis., 10(11):1286-1291 (2006).
  7. Castanheira M., Messer S. A., Rhomberg P. R., Pfaller M. A., Antifungal susceptibility patterns of a global collection of fungal isolates: results of the SENTRY Antifungal Surveillance Program (2013), Diagn. Microbiol. Infect. Dis., 85(2):200-204 (2016). Centers for Disease Control and Prevention. Clinical Alert to U.S. Healthcare Facilities - June 2016 | Fungal Diseases | CDC. Fungal Diseases. http://www.cdc.gov/fungal/diseases/candidiasis/candida-auris-alert.html. Published 2016. Accessed November 25, 2016.
  8. Chang C-H., Young-Xu Y., Kurth T., Orav JE., Chan A. K., The safety of oral antifungal treatments for superficial dermatophytosis and onychomycosis: a meta-analysis. Am. J. Med., 120(9):791-798 (2007).
  9. Chapman S. W., Dismukes W. E., Proia L. A., et al. Clinical practice guidelines for the management of blastomycosis: 2008 update by the Infectious Diseases Society of America., Clin. Infect. Dis., 46(12):1801-1812 (2008). Clancy C